These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35888774)

  • 1. Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition.
    Chokesuwattanaskul S; Fresneda Alarcon M; Mangalakumaran S; Grosman R; Cross AL; Chapman EA; Mason D; Moots RJ; Phelan MM; Wright HL
    Metabolites; 2022 Jul; 12(7):. PubMed ID: 35888774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
    Mitchell TS; Moots RJ; Wright HL
    Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks.
    Choe JY; Kim SK
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
    Taylor PC; Laedermann C; Alten R; Feist E; Choy E; Haladyj E; De La Torre I; Richette P; Finckh A; Tanaka Y
    J Clin Med; 2023 Jul; 12(13):. PubMed ID: 37445562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
    Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
    Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust intracellular metabolite extraction protocol for human neutrophil metabolic profiling.
    Chokesuwattanaskul S; Phelan MM; Edwards SW; Wright HL
    PLoS One; 2018; 13(12):e0209270. PubMed ID: 30571714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
    Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
    Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical JAK inhibitors for the treatment of rheumatoid arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    Expert Opin Pharmacother; 2016 Nov; 17(16):2215-2225. PubMed ID: 27690665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis.
    Crispino N; Ciccia F
    Clin Exp Rheumatol; 2021; 39(3):668-675. PubMed ID: 33200731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells.
    Golumba-Nagy V; Yan S; Steinbach-Knödgen E; Thiele J; Esser RL; Haak TH; Nikiforov A; Meyer A; Seeger-Nukpezah T; Kofler DM
    Physiol Rep; 2023 Oct; 11(19):e15829. PubMed ID: 37771106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
    Hu L; Liu R; Zhang L
    Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
    Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
    Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
    Iwata S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.